Abstract: The present invention discloses triazene analogs of the general formula (I) and formula (II), their tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts thereof for the metastatic malignant melanoma and other cancers including but not limited to lymphomas, sarcomas, carcinomas, and gliomas. The invention further discloses a process for the preparation of the above said triazene analogs of formula (I) and formula (II), and their pharmaceutically acceptable compositions.

Abstract: Disclosed herein are novel dietary supplement compositions comprising enriched 3-O-acetyl-11-keto-?-boswellic acid and enriched demethylated curcuminoids, wherein the composition exhibits anti-inflammatory, antiulcerogenic and anti-oxidant activities. Also disclosed are novel compositions comprising enriched 3-O-acetyl-11-keto-?-boswellic acid, enriched demethylated curcuminoids that have a synergistic effect on specific inhibition of—COX-2 and 5-LOX activity and optionally containing glucosamine, resveratrol, garlic extract, chondroitin, methlysulphonymethane, bromelain, serratiopeptidase, quercitine, gallic acid, caffeic acid, green tea extract, aspirin and ibuprofen.

Abstract: The current disclosure discloses acetogenin(s), extract(s)/fraction(s) standardized to acetogenin(s) comprising terminal ?,?-unsaturated-?-methyl-?-lactone moiety derived from Annona squamosa or their compositions for prevention, treatment, inhibition or controlling inflammation and immune related diseases or disorders mediated through cytokines/chemokines or other biomarkers. The disclosure further discloses said Annona squamosa derived acetogenin(s), extract(s)/fraction(s) or their compositions for prevention, treatment, inhibition or controlling metabolic diseases/disorders.

Abstract: Herbal compositions having anti-adipocyte fatty acid-binding protein (aP2), anti-5-lipoxygenase-activating protein (FLAP) and anti-Cysteinyl Leukotriene (CysLT)-1 receptor expression activity contain an extract of Boswellia serrata. More particularly, these herbal compositions comprise an effective amount of an enriched Boswellia extract containing from 10% to 99% by weight of 3-0-acetyl-11-keto-?-boswellic acid; and an effective amount of a second extract selected from the group consisting of an extract of Aegle marmelos, an extract of Zingiber officinale, an extract of Garcinia mangostana, and mixtures thereof. These may be used in dietary supplements or pharmaceutical formulations for controlling diseases associated with or related to inflammation. These diseases in particular include respiratory disorders such as asthma, allergic rhinitis, hay fever, type-1 hypersensitivity and mild allergies. The compositions can also be useful for skin care.

Abstract: Disclosed herein are novel dietary supplement compositions comprising enriched 3-O-acetyl-11-keto-?-boswellic acid and enriched demethylated curcuminoids, wherein the composition exhibits anti-inflammatory, antiulcerogenic and antioxidant activities. Also disclosed are novel compositions comprising enriched 3-O-acetyl-11-keto-?-boswellic acid, enriched demethylated curcuminoids that have a synergistic effect on specific inhibition of—COX-2 and 5-LOX activity and optionally containing glucosamine, resveratrol, garlic extract, chondroitin, methlysulphonymethane, bromelain, serratiopeptidase, quercitine, gallic acid, caffeic acid, green tea extract, aspirin and ibuprofen.

Abstract: The invention discloses herbal ingredient(s) derived from Ficus hispida comprising herb powder(s), extract(s), fraction(s), pure compound(s) or mixtures thereof and their compositions for alleviating metabolic disorders selected from metabolic syndrome, obesity, diabetes, atherosclerosis, endothelial dysfunction and other metabolic disorders or conditions; the for amelioration of different biological marker proteins and metabolic processes associated metabolic disorders.

Abstract: Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II): wherein the substituents R1, R2, R3, R6, and R7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.

Abstract: Nanoemulsified topical formulation comprising curcumin, tetrahydroxycurcumin (BDMC) and curcuminoid either alone or in combinations in an amount of 0.001% to 50% together with one or more pharmaceutically, nutraceutically or dietically acceptable excipient(s) or inactive ingredients, useful for the treatment of inflammation, various skin and oral disorders, mucosal disorders and other diseases associated or related thereof.

Abstract: Analogs of 3-O-acetyl-11-keto-beta-boswellic acid and their method of preparation are presented. The analogs may be used as anti-inflammatory and anti-cancer agents. The compounds inhibit 5-lipoxygenase enzyme and various cell lines related to inflammation as well as to cancer showing a significantly better efficacy when compared to the normal boswellic acids. The analogs are capable of controlling and treating various inflammatory diseases and cancers.

Abstract: A pharmaceutical composition for nasal administration comprising: a nanoemulsified curcumin component; a liquid medium for the curcumin component; and a pharmaceutically acceptable excipient. The curcumin component is a natural curcuminoid, a synthetic curcuminoid, a metabolite of a natural or synthetic curcuminoid, or a mixture thereof. The excipient is effective in increasing the bioavailability of the curcumin component.

Abstract: The invention relates pharmaceutical/dietary supplement/food ingredient(s) selected from the extract(s), fraction(s), active compound(s) and phytochemical(s) or mixtures thereof derived from Sphaeranthus indicus and their compositions, preferably in combination with at least one component selected from the extract(s), fraction(s), active compound(s) and phytochemical(s) or mixtures thereof derived from Garcinia mangostana. The ingredients and the composition(s) can be used for the control, prevention and treatment of obesity, metabolic syndrome, diabetes and other metabolic disorders, and also to regulate energy expenditure, prevention of atherosclerotic plaques in coronary artery and abdominal aorta, increase insulin sensitivity, prove glucose tolerance, lower triglyceride levels and balance glucose levels in mammals.

Abstract: A process for nanomulsification of highly lipophillic polyphenols compounds using non-ionic surfactant and a non-ionic co-solvent with the help of sonar energy, to enhance the aqueous solubility is disclosed herein.

Abstract: Aqueous ophthalmic compositions comprising natural or synthetic curcuminoids either alone or in combination, nonionic surfactant and co-solvent along with suitable ophthalmic excipients, effective in increasing the bioavailability of the active compounds when administered topically to the eye is disclosed herein.

Abstract: The present invention discloses synergistic nutraceutical or pharmaceutical or dietary supplement anti-inflammatory compositions comprising therapeutically effective combination of an extract selectively enriched in 3-O-acetyl-11-keto-?-boswellic acid (AKBA) derived from Boswellia serrata and Boswellia serrata non- acidic resin extract (BNRE). The composition(s) can be used to prevent, control and treat inflammation and several inflammatory related diseases including asthma, osteoarthritis, rheumatoid arthritis, endothelial dysfunction and the like. The invention further discloses the amelioration of pro-inflammator biomarker proteins or molecules, whose expression/production is altered during inflammatory diseases.

Abstract: The invention discloses a compound of formula (I) wherein, at least one of R1, R2, R3 and R4 is —C(?O)Rn and R1, R2R3 and R4 are H or CH3 and Rn is alkyl or alkenyl group. The alkenyl group have one or more number of double bonds either in cis form or trans form or both. In Rn, where n is 12 to 30 carbons; and pharmaceutically acceptable salt thereof. The said alkenyl groups are preferably selected from the group consisting of eicosapentaenoic acid (EPA) or DHA (docosahexaenoic acid). This invention further discloses processes for their preparation of compounds of formula I and pharmaceutical compositions that contain these compounds.

Abstract: This invention relates to novel corosolic acid analogs of the formula I, wherein R1, R2, R3, R4 and R5 are described herein. These compounds exhibit good hypoglycemic and 5-lipoxygenase inhibitory activities. They also inhibit tumour growth. Pharmaceutical compositions containing known adjutants and the title compounds are also within the scope of this invention.

Abstract: Pharmaceutical, cosmetic, nutraceutical and dietary compositions derived from Garcinia mangostana are rich in ?-mangostin and other demethylated xanthones. These compositions exhibit potent antioxidative activity and reduce inflammation. These compositions may be used in a method of treating TNF-?, and aP2 mediated disorders. The compositions are prepared by subjecting a hydroalcoholic extract of fruit pericarp (fruit hull) of Garcinia mangostana, wherein said hydroalcoholic extract comprises predominantly ?-mangostin, to demethylation in the presence of a Lewis acid, an organic base and a catalyst.

Abstract: A process for the production of ?-mangostin comprising the steps of preparing O-methyl ?-mangostin preferably from plants, subjecting the pure or partially pure O-methylated ?-mangostin to demethylation reaction procedure followed by purification of the said demethylated product to obtain pure ?-mangostin.

Abstract: Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II): wherein the substituents R1, R2, R3, R6, and R7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.

Abstract: Synergistic anti-adipogenic and pro-lipolytic compositions for the prevention and amelioration of adipogenesis and lipolysis mediated diseases, comprising at least two extracts selected from enriched demethylated curcuminoids obtained from Curcuma longa, Moringa oleifera and Murraya koenigii. The anti-adipogenic and pro-lipolytic compositions optionally contain one or more anti-obesic agents. These compositions are useful for preventing anti-inflammatory and free radical mediated diseases.